

myeloid dendritic cells. Therefore, enhanced expressions of TLR2, TLR4, and RIG-I in myeloid dendritic cells may be due to, not completely but in some part, the existence of HCV in cells or the exposure to endogenous IFN- α . To check this, it may be necessary to conduct studies with inoculation of HCV particles or transduction of the viral genome in myeloid dendritic cells.

In comparison of the results between the HCV and the HBV groups, the expressions of TLR2 and TLR4 in the HBV group were comparable with those from healthy donor group, suggesting that the induction of TLR2 and TLR4 in myeloid dendritic cells is unique in HCV infection. In contrast, the levels of RIG-I and LGP2 were comparable between the HCV and the HBV groups, both of which were higher than those from healthy donors. These results raise the possibility that, regardless of the difference of hepatitis virus, similar mechanisms may be involved in the induction of RIG-I and LGP2 in myeloid dendritic cells. In cells bearing HCV replicons, it has been reported that HCV NS3/4A inhibits TLR3 or RIG-I-mediated IFN- β induction by the cleavage of relevant adaptor molecules TRIF or IPS-1, respectively [Foy et al., 2005; Li et al., 2005]. In the present study, in myeloid dendritic cells from the HCV group, polyI:C-stimulated IFN- β , TNF- α , and IL-12 p70 induction is impaired. As for the adaptor molecules in TLR-dependent signals, TRIF and TRAF6 expression was lower in HCV-infected patients than those in healthy donors. Since it has been proven that the cleavage of TRIF hampers TLR3-mediated IFN production [Fitzgerald et al., 2003], the current study implies that lower expression of TRIF is involved in the inhibition of TLR3 or TLR4-mediated signals in myeloid dendritic cells. Of particular interest is the possibility that such reduction of TRIF and TRAF6 in myeloid dendritic cells is caused by the cleavage by NS3/4A, as shown in hepatoma cells [Foy et al., 2005; Li et al., 2005]. If this does occur, the inhibitor of NS3/4A serine protease may be able to restore TLR-dependent innate responses in myeloid dendritic cells, in addition to its potent suppressive ability of HCV replication. Machida et al. reported that enhanced expression of TLR4 in HCV-infected B cells is related to the TLR4-dependent up-regulation of IFN- β and IL-6, suggesting that TLR4-dependent signals are not impaired in B cells [Machida et al., 2006]. Further study is necessary to reveal whether HCV does actually influence innate immunity according to differences in blood cell types. In the current study, polyI:C or LPS-stimulated myeloid dendritic cells from HBV-infected patients induced lesser degree of IFN- β or TNF- α , respectively. Several investigators reported that the function of blood dendritic cells in HBV-infected patients were impaired [Tavakoli et al., 2004; van der Molen et al., 2004]. It is yet to be determined whether HBV infects to myeloid dendritic cells or not. The current study raises the possibility that distinct mechanisms are involved in the impairment of TLR or RIG-I pathway according to the difference of virus. Further study depending on expression as well as functional assay of virus recogni-

tion system in HBV infection is needed to clarify these important issues.

In contrast with RIG-I and LGP2, MDA-5 expression in myeloid dendritic cells from HCV-infected patients was comparable with that from healthy donors, suggesting that these cytosolic RNA sensors are regulated independently. Recently, it has been reported that RIG-I is expected to be involved in the detection of Flaviviridae, which HCV belong to, but MDA-5 is not [Hornung et al., 2006]. Active involvement of RIG-I in HCV infection has been reported, demonstrating that RIG-I, but not MDA-5, efficiently binds to secondary structured HCV RNA to confer induction of IFN- β [Saito et al., 2007]. In this study, although the polyI:C-stimulated cytokine response in patient myeloid dendritic cells was impeded, IPS-1 expression was higher than that in myeloid dendritic cells from the healthy donor group, suggesting a lesser possibility of IPS-1 as a cleavage target of HCV in myeloid dendritic cells. Alternatively, higher expression of LGP2 may contribute to the inhibitory machinery against RIG-I-mediated responses in myeloid dendritic cells, as reported elsewhere [Saito et al., 2007].

In summary, in myeloid dendritic cells from HCV-infected patients, innate cytokine responses were impaired regardless of the enhanced expressions of TLR2, TLR4, and RIG-I. These findings provide insights into the roles of the TLR/RIG-I system in the pathogenesis of HCV infection and their potentials as therapeutic targets for immune modulation.

REFERENCES

- Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE. 2004. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. *J Virol* 78: 13779–13792.
- Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. 2001. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. *Hepatology* 33:267–276.
- Doyle SE, O'Connell R, Vaidya SA, Chow EK, Yee K, Cheng G. 2003. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. *J Immunol* 170:3565–3571.
- El-Serag HB, Anand B, Richardson P, Rabeneck L. 2003. Association between hepatitis C infection and other infectious diseases: A case for targeted screening? *Am J Gastroenterol* 98:167–174.
- Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. *Nat Immunol* 4:491–496.
- Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-1 signaling. *Proc Natl Acad Sci USA* 102:2986–2991.
- Hornung V, Ellegast J, Kim S, Brozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. *Science* 314:994–997.
- Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. *Nat Immunol* 5:987–995.
- Kamori A, Kanto T, Kwang Limn C, Komoda Y, Oki C, Inoue M, Miyatake H, Itose I, Sakakibara M, Yakushijin T, Takehara T, Matsuura Y, Hayashi N. 2004. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. *Virology* 324:74–83.
- Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N.

2004. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. *J Infect Dis* 190:1919-1926.
- Lauer GM, Walker BD. 2001. Hepatitis C virus infection. *N Engl J Med* 345:41-52.
- Li K, Foy E, Ferreone JC, Nakamura M, Ferreone AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci USA* 102:2992-2997.
- Machida K, Cheng KT, Sung VM, Levine AM, Fong S, Lai MM. 2006. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. *J Virol* 80:866-874.
- Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M. 1999. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test. *J Clin Microbiol* 37:2793-2797.
- Pawlowsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. 2000. Standardization of hepatitis C virus RNA quantification. *Hepatology* 32:654-659.
- Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R, Visvanathan K. 2006. Toll-like receptor expression in chronic hepatitis C: Correlation with pro-inflammatory cytokine levels and liver injury. *Inflamm Res* 55:279-285.
- Rodrigue-Gervais IG, Jouan L, Beaulieu G, Sauve D, Bruneau J, Willems B, Sekaly RP, Lamer D. 2007. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. *J Virol* 81:5537-5546.
- Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale M Jr. 2007. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and L GP2. *Proc Natl Acad Sci USA* 104:582-587.
- Spanakis NE, Garinis GA, Alexopoulos EC, Patrinos GP, Menounos PG, Sklavounou A, Manolis EN, Gorgoulis VG, Valis D. 2002. Cytokine serum levels in patients with chronic HCV infection. *J Clin Lab Anal* 16:40-46.
- Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* 79:2689-2699.
- Szabo G, Dolganic A. 2005. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. *Immunobiology* 210:237-247.
- Tavakoli S, Schwerin W, Rohwer A, Hoffmann S, Weyer S, Weth R, Meisel H, Diepolder H, Geissler M, Galle PR, Lohr HF, Bocher WO. 2004. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. *J Gen Virol* 85:2829-2836.
- van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J, Janssen HL. 2004. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. *Hepatology* 40:738-746.
- Wedemeyer H, He XS, Nascimben M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. 2002. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. *J Immunol* 169:3447-3458.
- Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5:730-737.

Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma

Keisuke Kohga,^{1,5} Tetsuo Takehara,^{1,5} Tomohide Tatsumi,¹ Kazuyoshi Ohkawa,¹ Takuya Miyagi,¹ Naoki Hiramatsu,¹ Tatsuya Kanto,¹ Tsutomu Kasugai,² Kazuhiro Katayama,² Michio Kato³ and Norio Hayashi^{1,4}

¹Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871; ²Department of Gastroenterology and Hepatology, Osaka Koseinenkin Hospital, 4-2-27 Fukushima, Fukushima, Osaka, Osaka 553-0003; ³Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, 2-1-14 Hoenzaka, Chuoku, Osaka, Osaka 540-0006, Japan

(Received January 16, 2008/Revised April 8, 2008/Accepted April 11, 2008/Online publication July 29, 2008)

Soluble forms of major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) are increased in the sera of patients with malignancy and impair the antitumor immune response by downregulating expression of their cognate immunoreceptor natural killer group 2, member D (NKG2D). Recently, soluble MICA/B were reported to appear even in some premalignant diseases, raising questions about the impact of soluble MICA/B produced from tumors on the expression of NKG2D. The present study examined soluble MICA/B in chronic liver disease and hepatocellular carcinoma (HCC) and their involvement in the immune-cell expression of NKG2D during transcatheter arterial embolization for HCC. The levels of soluble MICA/B were significantly higher in chronic liver disease and HCC patients than in healthy volunteers. The progression of liver disease and that of the tumor were independent determinants for soluble MICA/B levels. Immunohistochemistry revealed that MICA/B were expressed not only in HCC tissue but also on hepatocytes in cirrhotic livers. The transcatheter arterial embolization therapy significantly decreased serum levels of soluble MICA, but not soluble MICB, and increased the NKG2D expression on natural killer cells and CD8-positive T cells; there was an inverse correlation between changes in soluble MICA levels and in NKG2D expression. In conclusion, although soluble MICA/B are produced from both HCC and premalignant cirrhotic livers, therapeutic intervention for HCC can reduce the levels of soluble MICA and thereby upregulate the expression of NKG2D. Cancer therapy may have a beneficial effect on NKG2D-mediated antitumor immunity. (*Cancer Sci* 2008; 99: 1643–1649)

MHC class I-related chain A and B, glycoproteins expressed on the cellular membrane, are ligands for NKG2D expressed on a variety of immune cells.⁽¹⁾ In contrast to classical MHC class I molecules, MICA/B are expressed rarely on normal cells but frequently on tumor cells, including colon cancer, prostate cancer, HCC, and brain tumors.^(2–5) The engagement of MICA/B and NKG2D strongly activates NK cells and costimulates T cells, enhancing their cytolytic ability and cytokine production.⁽⁶⁾ Thus, the MICA/B–NKG2D pathway is an important mechanism by which the host immune system recognizes and kills transformed cells.⁽⁷⁾ In addition to those membrane-bound forms, MICA/B are also cleaved proteolytically from tumor cells and appear as soluble forms in sera of patients with malignancy.^(8–10) The levels of NKG2D expression tend to be decreased in patients with high levels of soluble MICA/B.⁽⁴⁾ In addition, sera from those patients can downregulate NKG2D expression *in vitro*.^(5,11) These data

suggest that soluble MICA/B in the circulation downregulate NKG2D expression and disturb NKG2D-mediated antitumor immunity, raising the possibility that cancer therapy might reduce the serum levels of soluble MICA/B and thereby improve the NKG2D-related immune environment. However, this possibility has not been addressed directly by examining soluble MICA/B and NKG2D expression in a cohort of patients before and after cancer therapy. Furthermore, recent reports by Holdenrieder *et al.* demonstrating that soluble MICA/B are increased not only in malignant disease but also in some benign diseases, such as of the gastrointestinal tract, gynecologic organs, and lungs, raise questions about the impact of cancer therapy on modulating soluble MICA/B levels.^(12,13)

Hepatocellular carcinoma is one of the leading causes of cancer death worldwide. Chronic liver disease caused by hepatitis virus infection and non-alcoholic steatohepatitis leads to a predisposition for HCC; liver cirrhosis, in particular, is considered to be a premalignant condition.^(14,15) With regard to treatment, surgical resection or percutaneous techniques such as ethanol injection and radiofrequency ablation are considered to be choices for curable treatment of localized HCC, whereas TAE is a well-established technique for unresectable HCC.⁽¹⁶⁾ We reported previously that soluble MICA could be detected in sera of HCC patients.⁽¹⁷⁾ However, the clinical significance of the soluble forms of NKG2D ligands in liver disease has not yet been established in a comprehensive manner, because the previous study was conducted on a small number of patients, did not include patients with premalignant conditions such as liver cirrhosis, and did not analyze its closely related molecule MICB. Furthermore, influences of therapeutic intervention on soluble NKG2D ligands in patients have been unclear. In the present study, we examined soluble MICA and soluble MICB in sera from a large number of patients with chronic liver diseases and HCC and their impact on NKG2D expression on immune cells during TAE therapy for HCC.

*To whom correspondence should be addressed.

E-mail: hayashin@hl.med.osaka-u.ac.jp

Keisuke Kohga and Tetsuo Takehara contributed equally to this work.

Abbreviations: APC, allophycocyanin; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; HCC, hepatocellular carcinoma; MFI, mean fluorescence intensity; MICA/B, major histocompatibility complex (MHC) class I-related chain A and B; NK, natural killer; NKG2D, natural killer group 2, member D; PBMC, peripheral blood mononuclear cell; PE, phycoerythrin; TAE, transcatheter arterial embolization; TNM, tumor node metastasis.

Table 1. Control and patient characteristics

Characteristic	Healthy control	Chronic hepatitis	Liver cirrhosis	HCC
Number	104	141	104	232
Sex (male/female)	49/55	78/63	60/44	177/55*
Age (years)	62 ± 15	55 ± 13**	61 ± 12	68 ± 9***
Etiology				
HBV/HCV	-	27/107	12/78	37/187
Alcohol/NASH	-	0/5/	2/1/	4/0/
AIH/PBC/others	-	2/0/0	1/6/4	0/0/3
Child-Pugh (A/B/C)	-	-	34/27/26	131/84/17****
TNM stage (I/II/III/IV)	-	-	-	59/68/64/39

AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; TNM, tumor node metastasis. * $P < 0.05$ vs control, hepatitis, and cirrhosis by χ^2 -test; ** $P < 0.05$ vs control, cirrhosis, and HCC by ANOVA and post hoc Bonferroni test; *** $P < 0.05$ vs control, hepatitis, and cirrhosis by ANOVA and post hoc Bonferroni test; **** $P < 0.05$ vs cirrhosis by χ^2 -test.

Materials and Methods

Stock sera from patients with chronic liver disease and HCC. We used frozen stock sera obtained from consecutive patients with chronic liver disease who had been registered at our institute from February 2002 to April 2006. They included 141 patients with chronic hepatitis, 104 patients with liver cirrhosis, and 232 patients with HCC. The differential diagnosis between chronic hepatitis and liver cirrhosis was basically from liver biopsy ($n = 98$), but for those who had not undergone biopsy the diagnosis was based on clinical findings from the aspartate aminotransferase/platelet ratio index (APRI) score.⁽¹⁸⁾ Diagnosis of HCC was based on unequivocal clinical and imaging data. The control group consisted of 104 healthy volunteers of an age range similar to the liver cirrhosis group. Table 1 summarizes the control and patient characteristics of age, sex, etiology of liver disease, Child-Pugh classification, and TNM staging of HCC. Child-Pugh classification is a well-established index for progression of liver disease in cirrhotic patients where A, B, and C indicate compensated cirrhosis, mildly decompensated cirrhosis, and severely decompensated cirrhosis, respectively. The TNM staging adopted in the present study was that modified by the Liver Cancer Study Group of Japan.⁽¹⁶⁾

Detection of soluble MICA/B by ELISA. Serum levels of soluble MICA and soluble MICB were determined differentially by commercially available ELISA kits (R & D Systems, Minneapolis, MN, USA). In preliminary experiments, we determined the median intra-assay variation ($n = 5$) to be between 3.5 and 5.6% for soluble MICA and between 2.4 and 7.8% for soluble MICB, and the median interassay variation ($n = 5$) to be between 12.8 and 18.9% for soluble MICA and between 15.2 and 18.7% for soluble MICB.

Detection of MICA/B on liver tissues by immunohistochemistry. The human liver tissues examined were one normal liver, three from those at fibrosis stages 1 and 2 of chronic hepatitis, five from liver cirrhosis (fibrosis stage 4) patients, and five from HCC patients. Paraffin-embedded liver sections were deparaffinized, heat-inactivated by a microwave oven and then subjected to immunohistochemical staining using the ABC procedure (Vector Laboratories, Burlingame, CA, USA). The primary antibody used was 6D4 monoclonal antibody, which recognizes the $\alpha 1$ and $\alpha 2$ domains of MIC molecules shared by both MICA and MICB.⁽²⁾ To confirm the specificity of the staining, the 6D4 antibody was incubated with recombinant MICA (R & D Systems) for 2 h and then applied to liver sections in parallel with staining of the primary antibody as the absorption test.

Table 2. Characteristics of hepatocellular carcinoma patients

Characteristic	TAE-treated group	Non-treated group
Number	38	21
Sex (male/female)	28/10	17/4
Age (years)	75 ± 11	74 ± 8
Etiology (HBV/HCV)	2/36	1/21
Child-Pugh (A/B/C)	29/9/0	16/5/0
TNM stage (I/II/III/IV)	4/20/14/0	2/11/8/0

HBV, hepatitis B virus; HCV, hepatitis C virus; TAE, transcatheter arterial embolization; TNM, tumor node metastasis.

Detection of membrane-bound and soluble forms of MICA/B on cultured cells. HepG2 hepatoma cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Human non-transformed hepatocytes were purchased from Cambrex Bio Science (Charles City, IA, USA) and cultured according to the manufacturer's instructions. For detection of membrane-bound MICA/B, a single-cell suspension was stained with PE-labeled 6D4 monoclonal (R & D Systems) antibody, fixed with 2% paraformaldehyde, and then subjected to flow cytometric analysis. The culture supernatants were subjected to analysis of soluble forms of MICA and MICB using the above-mentioned ELISA assay.

Patients with HCC and TAE therapy. Thirty-eight patients with HCC admitted to our institution for TAE therapy were enrolled prospectively in the present study. TAE was carried out by the standard procedure using an emulsion of farmorubicin and lipiodol followed by gelatin sponge particles. Blood samples were collected before and 2 weeks after TAE therapy. Twenty-one patients with HCC, matching the TAE group with respect to TNM stage and Child-Pugh score, were also enrolled as controls (Table 2). Blood samples were collected twice at a 2-week interval. Written informed consent was received from all patients and the study protocol was approved by the Ethical Committee of Clinical Research at Osaka University Hospital.

Natural killer cell analysis. PBMC were isolated from heparinized venous blood by a standard procedure. PBMC were stained with FITC-labeled anti-CD3 antibody, APC-labeled anti-CD56 antibody, and PE-labeled anti-NKG2D antibody. They were also stained with FITC-labeled anti-CD3 antibody, APC-labeled anti-CD8 antibody, and PE-labeled anti-NKG2D antibody. All antibodies were purchased from Becton Dickinson (San Jose, CA, USA). NKG2D expression on NK cells (defined as CD56-positive and CD3-negative cells) and CD8-positive T cells (defined as CD3-positive and CD8-positive cells) were analyzed by flow cytometry. As a control, corresponding fluorescence-labeled irrelevant antibodies were used. As most NK and CD8-positive T cells express NKG2D, the levels of expression were evaluated by the mean fluorescence intensity of the stained cells.

Statistics. Values were expressed as the median and interquartile range as a box plot, and the 10th and 90th percentiles as a horizontal bar. For comparison of more than two groups, the Kruskal-Wallis rank sum test was used. If the Kruskal-Wallis test was significant, post hoc multiple comparisons were carried out using the Steel-Dwass procedure. Differences between pretreatment and post-treatment values were tested by paired t -test. $P < 0.05$ was considered statistically significant.

Results

Soluble MICA and soluble MICB in chronic liver disease and HCC. Soluble MICA and soluble MICB were assessed in sera from patients with chronic hepatitis, liver cirrhosis, and HCC as well as healthy volunteers. There was a stepwise increase in the levels of both soluble MICA and soluble MICB from hepatitis




Fig. 1. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) in chronic liver disease and hepatocellular carcinoma (HCC). (a) Soluble MICA and soluble MICB levels in serum samples of healthy controls (HC), chronic hepatitis (CH), liver cirrhosis (LC), and HCC. (b) Soluble MICA and soluble MICB are associated with the progression of liver disease. Data on cirrhotic patients were stratified based on Child-Pugh classification. (c,d) Soluble MICA and soluble MICB are associated with the progression of tumors. (c) Data on cirrhosis and HCC patients were classified into three groups: patients with absence of HCC (cirrhosis), patients with low-grade HCC (tumor node metastasis [TNM] stage I and II), and patients with high-grade HCC (TNM stage III and IV). (d) To exclude the possibility of progression of liver disease being involved in increase in soluble MICA/B, soluble MICA/B levels were compared among the three groups of Child-Pugh classification A. Data are represented as box plots (median values, 10th, 25th, 75th, and 90th percentiles). The number in parentheses indicates the number of patients in each group. * $P < 0.05$ by Kruskal-Wallis test and post hoc Steel-Dwass test.

to HCC (Fig. 1a). Although the difference between hepatitis patients and healthy volunteers was modest, both of the levels were clearly higher in patients with liver cirrhosis and HCC than in normal volunteers or hepatitis patients. To examine whether the progression of liver disease in cirrhotic patients affects the levels of soluble MICA/B, cirrhotic patients were stratified based on Child-Pugh classification. The levels of both soluble MICA and MICB were increased significantly with the progression of liver disease (Fig. 1b).

Hepatocellular carcinoma often develops from cirrhotic liver and most patients with HCC included in the present study had complications from cirrhosis. To examine whether the development and progression of HCC contributes to increasing soluble MICA/B, patients with liver cirrhosis and those with HCC were classified into three groups: those with an absence of HCC, low-grade HCC (TNM stage I/II) and high-grade HCC (TNM stage III/IV). There was no significant difference in soluble MICA or soluble MICB between patients without HCC and

low-grade HCC patients. However, the high-grade HCC patients showed significantly higher levels of soluble MICA or soluble MICB than patients without HCC or the low-grade HCC patients (Fig. 1c). To exclude the possibility of the progression of liver disease affecting the increases in soluble MICA/B in high-grade HCC, we selected and analyzed only the Child-Pugh A patients. In this subgroup of patients, the levels of soluble MICA/B were also significantly higher with high-grade HCC than with low-grade HCC or the absence of HCC (Fig. 1d). Thus, the progression of liver disease and that of the tumor independently affects the levels of soluble MICA or soluble MICB.

MICA/B expression in liver tissues and production of soluble MICA/B. The increase in soluble MICA/B in cirrhotic patients suggests that MICA/B may be expressed in cirrhotic livers. We therefore examined MICA/B expression by immunohistochemistry in various human tissues including normal liver, chronic hepatitis (F1 and F2 stage), liver cirrhosis, and HCC (Fig. 2a). MICA was detected clearly in four of five HCC tissues, agreeing with a




Fig. 2. Expression of major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) and production of their soluble forms. (a) Immunohistochemical detection of MICA/B in liver tissues. Representative staining with anti-MICA/B monoclonal antibody (6D4) is shown for normal liver, chronic hepatitis (F1 stage), liver cirrhosis (F4 stage), and hepatocellular carcinoma (HCC) (upper panel). As a control, 6D4 monoclonal antibody was preabsorbed with recombinant MICA and applied to the neighboring corresponding sections (lower panel). (b) Flow cytometric analysis of surface expression of MICA/B on HepG2 hepatoma cells and non-transformed hepatocytes. Open and closed histograms represent the staining of anti-MICA/B antibody (6D4) and control antibody, respectively. (c) Soluble MICA and soluble MICB released from HepG2 hepatoma cells and non-transformed hepatocytes. Cells were seeded in a subconfluent condition and cultured for 48 h. The culture supernatants were applied for analysis of soluble MICA and soluble MICB by enzyme-linked immunosorbent assay. ND, not detected.

previous report.⁽³⁾ Importantly, hepatocytes in four of five cirrhotic livers were positive for MICA/B, whereas MICA/B were not detected in hepatocytes from normal liver or liver at the early stage of chronic hepatitis.

We also examined the expression of MICA/B on normal hepatocytes and HepG2 hepatoma cells. Flow cytometric analysis revealed that HepG2 cells expressed MICA/B on the cell surface (Fig. 2b). Both soluble forms of MICA and MICB were detected in the supernatant of HepG2 cells cultured for 48 h (Fig. 2c). In contrast, non-transformed hepatocytes expressed MICA/B faintly and soluble MICA/B could not be detected in their culture supernatant. This observation supported the idea that both soluble MICA and soluble MICB are produced from MICA/B-expressing hepatic cells.

Downregulation of soluble MICA levels by TAE. The above findings suggest that soluble MICA/B are produced from cirrhotic livers as well as HCC. In addition, the progression of the tumor is an important determinant of soluble MICA/B independent of the progression of liver disease. We then asked the question of whether therapeutic intervention of HCC would reduce the levels of soluble MICA or soluble MICB and affect the levels of NKG2D expression on immune cells. We prospectively analyzed the levels of soluble MICA/B and NKG2D expression in 38 HCC patients before and 2 weeks after TAE therapy. As a control, 21 HCC patients who did not receive TAE therapy but were matched to the TAE group with respect to clinical characteristics were analyzed over a 2-week interval.




Fig. 3. Soluble major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) during transcatheter arterial embolization (TAE) therapy. (a) Soluble MICA and soluble MICB were measured for 38 patients before and 2 weeks after TAE therapy. Twenty-one patients who did not receive TAE therapy served as controls, with soluble MICA/B being measured twice with a 2-week interval. (b) TAE-treated patients were divided into two groups: Child-Pugh A ($n = 29$) and Child-Pugh B and C ($n = 9$). (c) TAE-treated patients were divided into two groups: low-grade hepatocellular carcinoma (HCC) ($n = 24$) and high-grade HCC ($n = 14$). * $P < 0.05$ by paired t-test.

In the TAE-treated group, the levels of soluble MICA were decreased significantly 2 weeks after TAE therapy compared with those before TAE (Fig. 3a). In contrast, TAE did not affect the levels of soluble MICB. Neither the levels of soluble MICA nor those of soluble MICB changed during the 2-week interval in HCC patients not receiving TAE therapy. As the progression of liver disease and that of the tumor affects the levels of soluble

MICA/B, TAE-treated patients were divided according to their Child-Pugh stage or tumor stage. The levels of soluble MICA decreased significantly after TAE therapy in Child-Pugh A patients but not in Child-Pugh B and C patients (Fig. 3b). Interestingly, Child-Pugh A patients showed a significant decrease even in soluble MICB levels after TAE therapy but Child-Pugh B and C patients did not. As for tumor stage, a significant decrease in




Fig. 4. Natural killer group 2, member D (NKG2D) expression during transcatheter arterial embolization (TAE) therapy. (a) NKG2D expression on natural killer (NK) cells and CD8-positive T cells. NKG2D expression on immune cells was analyzed in 38 patients before and 2 weeks after TAE therapy. Twenty-one patients who did not receive TAE therapy served as a control by measuring NKG2D expression for 2-week interval. NKG2D expression on each cell type was evaluated by mean fluorescence intensity (MFI). * $P < 0.05$ by paired t-test. (b) Correlation between change of soluble MICA and that of NKG2D expression on NK cells or CD8-positive T cells.

soluble MICA levels after TAE therapy was found in low-grade HCC but not in high-grade HCC (Fig. 3c). The levels of MICB did not change in the low-grade or high-grade HCC groups.

Upregulation of NKG2D expression by TAE. The number of PBMC as well as NK and T-cell subsets did not change over the 2-week interval in both the control and TAE-treated patients (data not shown). However, the levels of NKG2D expression on NK and CD8-positive T cells increased significantly upon TAE therapy, but not in the control group (Fig. 4a). To examine the involvement of soluble MICA in NKG2D expression, we analyzed the relationship of changes between soluble MICA and NKG2D expression in HCC patients. Change in soluble MICA was correlated inversely with changes in NKG2D expression on NK and CD8-positive T cells (Fig. 4b). There was no significant correlation between changes in soluble MICB and NKG2D expression (data not shown).

Discussion

In the present study, we demonstrated that soluble MICA/B increases with the progression of chronic liver disease as well as the progression of HCC. Increases in soluble MICA/B in advanced stages of tumors have been reported in some malignancies.⁽¹²⁾ However, little is known about soluble MICA/B in the premalignant

condition. Recently, Holdenrieder *et al.* examined soluble MICA/B levels in benign as well as malignant diseases from heterogeneous organs.^(12,13) They found that benign diseases, such as gastrointestinal tract adenoma, pulmonary infectious disease, and gynecologic benign tumors, showed intermediate levels of soluble MICA/B between healthy controls and malignant disease. Our present findings not only agree with theirs, but also provide evidence that soluble MICA/B increases in premalignant conditions such as liver cirrhosis.

Malignant disease is known to lead frequently to the expression of MICA/B.⁽²⁾ In contrast, their expression in premalignant tissues has not been fully elucidated. In the present study, MICA/B were found to be expressed in liver cirrhosis as well as HCC tissues, but not in the early stages of chronic hepatitis or in normal liver. This finding is consistent with the tendencies observed for serum-soluble MICA/B levels in chronic liver disease and HCC. Analysis of cultured cells also revealed that MICA/B expressed on hepatoma cells is released spontaneously into the culture supernatant as soluble forms, supporting the idea that MICA/B expressed in the liver may be released into the circulation. In contrast, MICA/B were not expressed on nor released from cultured non-transformed hepatocytes, which is consistent with the *in vivo* immunohistochemical finding. An issue to be resolved is the underlying mechanism by which non-transformed

hepatocytes express and release MICA/B in pathological conditions such as liver cirrhosis. Recently, it was reported that non-transformed pulmonary epithelial cells can express MICA/B under oxidative stress-inducing conditions.⁽¹⁹⁾ It was also reported that MICA/B are upregulated in non-tumor cell lines by genotoxic stress.⁽²⁰⁾ It has been speculated that oxidative and genotoxic stresses may accumulate in hepatocytes in chronic diseased liver. Thus, it is possible that those stresses may contribute to MICA/B expression in chronic diseased liver. Further study is needed to clarify this issue.

MICA/B expression in the premalignant condition raises the question of which contributes more to the production of soluble MICA/B, malignant tissues or non-malignant tissues. To address this question we analyzed the levels of soluble MICA/B in HCC patients before and after therapeutic intervention. Among treatments for HCC, TAE is a well-established technique for unresectable, advanced HCC.⁽¹⁶⁾ To include HCC patients who show relatively high levels of soluble MICA/B, we chose a cohort of patients who received the TAE therapy in the present study. The data indicated that the levels of soluble MICA, but not those of soluble MICB, decreased after TAE therapy. It is not clear why soluble MICB did not change during TAE therapy. One possibility is that soluble MICB production from non-tumor livers may be relatively high compared with that of soluble MICA. In our subpopulation analysis, Child-Pugh A patients showed a significant decrease in soluble MICB levels after TAE therapy. In general, TAE therapy is more effective for Child-Pugh A patients than Child-Pugh B or C patients because the former is better able to tolerate the large dose of lipiodol emulsion and gelatin sponge that is necessary for efficient antitumor effect. Indeed, Child-Pugh A patients in our cohort showed a larger decrease in α -fetoprotein levels after TAE therapy than Child-Pugh B and C patients, although the difference did not reach a significant level (our unpublished data). Thus, TAE therapy might reduce the levels of soluble MICB when it achieves substantial antitumor effect. Most importantly, the data also indicated that NKG2D expression on immune cells was clearly ameliorated with TAE therapy. Furthermore, there was an inverse correlation between a reduction in soluble MICA and upregulation of NKG2D, suggesting the link between soluble MICA and NKG2D expression in cancer patients.

It is generally speculated that soluble MICA/B produced from tumors may deactivate NKG2D-mediated immune responses.^(8,9) *In vitro* experiment indicates that soluble MICA could down-regulate NKG2D expression and effector cell function. However, the regulation by soluble forms of NKG2D ligands would be more complicated *in vivo*. First, soluble forms of NKG2D ligands could be produced not only from malignant tissues but also from non-malignant tissues, as shown in the present study. Second, MHC-encoded MICA/B may not be the sole family of proteins serving as NKG2D ligands. Non-MHC-encoded UL16-binding proteins also act as NKG2D ligands and were very recently found to be cleaved proteolytically from tumor cells.⁽²¹⁾ The present study provides evidence that soluble MICA is derived, at least in part, from HCC and regulates NKG2D expression on NK and CD8-positive T cells. Although several species of soluble NKG2D ligands may exist in the circulation, the present study suggests that soluble MICA regulates NKG2D expression directly in cancer patients.

In conclusion, soluble MICA and MICB are significantly increased in the sera of patients not only with HCC but also with chronic liver disease. Soluble MICA/B increases together with the progression of liver disease as well as the tumor. Therapeutic intervention for HCC leads to reduction of soluble MICA levels in association with upregulation of NKG2D on immune cells, offering *in vivo* evidence of soluble MICA regulating NKG2D expression. Thus, cancer therapy may have a beneficial effect on the NKG2D-mediated immune response even if some of the soluble NKG2D ligands are produced from non-cancerous premalignant tissues.

Acknowledgments

We sincerely thank Dr Veronika Groh and Dr Thomas Spies (Fred Hutchinson Cancer Research Center, Seattle, WA, USA) for providing 6D4 antibody and Dr Alexander Steinle (University Tübingen, Tübingen, Baden-Württemberg, Germany) for providing the RSV-MICA*04 and control plasmids. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan and a Grant-in-Aid for Research on hepatitis and bovine spongiform encephalopathy (BSE) from the Ministry of Health, Labor and Welfare, Japan.

References

- Bauer S, Groh V, Wu J *et al*. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 1999; **285**: 727-9.
- Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived $\gamma\delta$ T cells of MICA and MICB. *Proc Natl Acad Sci USA* 1999; **96**: 6879-84.
- Jinushi M, Takehara T, Tatsumi T *et al*. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. *Int J Cancer* 2003; **104**: 354-61.
- Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. *J Clin Invest* 2004; **114**: 560-8.
- Raffaghello L, Prigione I, Airolidi I *et al*. Downregulation and/or release of NKG2D ligands as an immune evasion strategy of human neuroblastoma. *Neoplasia* 2004; **6**: 558-68.
- Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. *J Clin Immunol* 2005; **25**: 534-40.
- Caudert JD, Held W. The role of the NKG2D receptor for tumor immunity. *Semin Cancer Biol* 2006; **16**: 333-43.
- Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. *Nature* 2002; **419**: 734-8.
- Salih HR, Rammensee HG, Steinle A. Downregulation of MICA on human tumors by proteolytic shedding. *J Immunol* 2002; **169**: 4098-102.
- Salih HR, Antropius H, Giesecke F *et al*. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood* 2003; **102**: 1389-96.
- Mincheva-Nilsson L, Nagaeva O, Chen T *et al*. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on

- peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. *J Immunol* 2006; **176**: 3585-92.
- Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. *Int J Cancer* 2006; **118**: 684-7.
- Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih RH. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. *Cancer Immunol Immunother* 2006; **55**: 1584-9.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; **127**: S35-50.
- Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; **127**: S5-16.
- Takayasu K, Arii S, Ikai I *et al*. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* 2006; **131**: 461-9.
- Jinushi M, Takehara T, Tatsumi T *et al*. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. *J Hepatol* 2005; **43**: 1013-20.
- Wai CT, Greenson JK, Fontana RJ *et al*. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-26.
- Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, Cosman D. NKG2D ligands are expressed on stressed human airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2006; **291**: L222-31.
- Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature* 2005; **436**: 1186-90.
- Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor. *Cancer Res* 2006; **66**: 2520-6.

A New Prognostic System for Hepatocellular Carcinoma Including Recurrent Cases

A Study of 861 Patients in a Single Institution

Takashi Toyama, MD, PhD,* Naoki Hiramatsu, MD, PhD,† Takayuki Yakushijin, MD, PhD,† Tsugiko Oze, MD,† Fumihiko Nakanishi, MD, PhD,† Masakazu Yasumaru, MD, PhD,† Kiyoshi Mochizuki, MD, PhD,† Tatsuya Kanto, MD, PhD,† Tetsuo Takehara, MD, PhD,† Akinori Kasahara, MD, PhD,‡ and Norio Hayashi, MD, PhD†

(*J Clin Gastroenterol* 2008;42:317-322)

Objective: To manage hepatocellular carcinoma (HCC) patients surviving for a long term, the treatment strategy for recurrent cancer is as important as that for the initial treatment. However, no prognostic scoring system has been available for patients with HCC recurrence. The purpose of this study was to develop a new staging system for deciding the treatment strategy not only for first-time diagnosed patients but also for recurrent patients.

Methods: A total of 861 cases diagnosed at our single institution from 1993 to 2003 were included. Overall survival was the only end point. The Cox model was used for multivariate analyses.

Results: As of August 2004, 344 cases (59%) had died. Overall median survival time was 41 months. For multivariate Cox regression analysis, independent predictive factors of survival were the number of recurrences, the Child-Pugh score, 3 nodules less than 3 cm and none of vascular invasion, and the α -fetoprotein level. A simple scoring system was thus developed, assigning scores (0/1) to the 4 covariates of the final model. Compared with the other scoring systems, the new scoring system has a greater discriminant ability.

Conclusions: We concluded that our scoring system can serve as a new prognostic system that reflects the spread of HCC, treatment response, and liver function. It should be very useful as the only method which can be applied for patients with recurrence.

Key Words: hepatocellular carcinoma, recurrence, staging system, predictive factor, cox regression analysis

Received for publication December 6, 2006; accepted May 8, 2007. From the *Liver Research Center, Rhode Island Hospital/Brown Medical School, Providence, RI; Departments of †Gastroenterology and Hepatology; and ‡General Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

The authors declare no conflict of interest.

The authors confirm that there is no financial arrangement from the manufacturer with this study.

Reprints: Takashi Toyama, MD, PhD, Liver Research Center, Rhode Island Hospital/Brown Medical School, 55 Claverick Street, Providence, RI 02903 (e-mail: toyama.takashi@gmail.com).

Copyright © 2008 by Lippincott Williams & Wilkins

Recently, various nonsurgical treatment modalities for hepatocellular carcinoma (HCC) have been developed and surgical techniques have been also improved.^{1,2} However, HCC with cirrhosis remains one of the diseases that is extremely difficult to manage, because survival in HCC is not predominantly based on the biology of the tumor, but also on the underlying hepatic function. Actually, we need consider 2 distinctive features in planning the HCC treatment from other cancers. First, even if HCC can be completely treated, the residual cirrhotic liver displays a high risk of recurrence, including new primary cancers.³⁻⁵ Second, most options for the treatment of HCC lead to a decrease in the reserved hepatic function. In other words, they take the risk of future liver failure in return for HCC treatment. Taken together, the complexity of these factors makes HCC management difficult.

The prognosis of HCC patients is highly variable and hard to predict, which makes it difficult to effectively treat patients or to design good clinical trials. To provide guides for assessing disease severity and making therapeutic decisions, several staging or prognostic scoring systems for HCC have been proposed: the Cancer of the Liver Italian Program (CLIP) score,⁶ BCLC staging,⁷ and Japan Integrated Staging (JIS) scoring system,⁸ which were produced on the basis of prognostic values. These staging systems can be used for assessing the prognosis of HCC patients as well as the efficiency of therapeutic modalities. Although these systems may be useful for predicting the prognosis of HCC patients at the time of the initial treatment,⁹⁻¹¹ there is considerable doubt about whether these systems are suitable for cases of recurrent cancer, because they cannot distinguish HCC diagnosed for the first time from recurrent HCC. In clinical practice, recurrent HCC patients are encountered 2.5 times more frequently in our institution than first-time HCC patients. Because the development of screening and follow-up programs and the improvement of radiologic techniques have facilitated the recognition of HCC at an earlier

stage,^{12,13} it has become possible to repeatedly apply curative treatments.

To manage HCC patients surviving for a long term, preparing the treatment strategy for recurrent cancer becomes more important than that for initial treatment. This makes it important to predict the prognosis of recurrent patients. In other words, every time HCC is diagnosed, the prognostic value should be assessed, and then a treatment strategy should be decided. However, no attempts have been made to include prediction of the prognosis of recurrent HCC patients. The purpose of this article is to propose a new prognostic scoring system, which can be useful for deciding the treatment strategy not only for first-time diagnosed patients but also for recurrent HCC patients.

PATIENTS AND METHODS

Study Population

All (888) consecutive adult patients who were diagnosed as HCC and registered with the Division of Internal Medicine in the Osaka University Hospital between 1993 and 2003, were eligible for this study. Sixteen patients who could not be confirmed as having HCC were excluded. Three patients who underwent liver transplantation were also excluded. Eight patients who had local recurrences within 6 months were excluded because their admissions were not for the recurrent tumor but rather for the residual tumors caused by the insufficient ablation therapy. Thus, 861 patients composed the study population. The patient data were collected with both a survey of original medical records and access to the hospital information system. The patient data set was divided into 2 data sets for a split-sample validation procedure,¹⁴ one set being retrospectively collected patients ($n = 578$) between September 1, 1993 and December 31, 2001, and the other being prospectively collected patients ($n = 283$) with the hospital database system between January 1, 2002 and December 31, 2003. The former was used as a training sample to construct a prognostic scoring system; the latter was used as a validation sample for the validation of the generated classification. HCC diagnosis was mainly established by the concomitant finding of 2 imaging techniques ($n = 438$), showing a nodule with arterial hypervascularization and portal hypovascularization, or by a positive imaging technique, showing hypervascularization associated with elevation of α -fetoprotein (AFP) or protein induced by vitamin K absence II (PIVKA-II) ($n = 272$). In addition, even if the above-mentioned features were not observed, target biopsy was performed when the findings of ultrasonography were consistent with HCC ($n = 151$). Details of the treatment modality showed that trans-catheter arterial chemoembolization alone or combined with percutaneous tumor ablation were mainly performed ($n = 306$ and 301, respectively). The number of patients treated with surgical resection, percutaneous tumor ablation alone, and best supportive care were 46, 188, and 20 respectively.

Statistical Methods

Overall survival was the only end point used in the analysis. It was defined as the time elapsed from the date of diagnosis and either the date of death related to liver disease or the date of the last follow-up information, with the final evaluation conducted on August 31, 2004. Patients lost before the last collection of follow-up information were censored at the time of their last visit. One hundred thirty-one of the 238 censored cases in the training sample were alive at the end of the period, whereas 22 patients had died from other diseases and 85 were lost to follow-up owing to change of residence ($n = 21$), introduction of a hospital near their residence ($n = 50$), and unknown reasons ($n = 14$). Two hundred and two of the 223 censored cases in the validation sample were alive, 3 patients died from other diseases, and 19 cases were lost to follow-up owing to the change of residence ($n = 1$), introduction of a hospital near their residence ($n = 11$), and unknown reasons ($n = 7$). Judging from the data at their last visit, all of the censored samples were considered to be independent of the future value of the hazard for the individual, in other words, they were noninformative censored cases. Figure 1 shows a schematic overview of investigated patients and dropouts for training and validation sample.

The following variables were used for the analysis: age and sex of the patient, date of HCC diagnosis, date of death or of last available information, viral status, the number of HCC recurrences, Child-Pugh score, the largest tumor size, tumor number, vascular invasion, AFP level, and PIVKA-II level. The cut-off levels of continuous variables were chosen on the basis of clinical meaning. For each variable, missing data were not used in the analysis if they accounted for less than 10% of the cases.

Univariate survival curves were estimated using the Kaplan-Meier method¹⁵ and compared by means of the log-rank test.¹⁶ The prognostic impact of the categories was assessed by means of the observed/expected ratio, as described previously.⁶ Of the factors affecting patient survival in univariate analysis, baseline predictors were identified by the Akaike information criterion in a stepwise algorithm.¹⁷ Next, a Cox proportional hazard




FIGURE 1. Schematic overview of included patients and dropouts for training and validation sample.

regression model was used for multivariate analyses.¹⁸ Proportional hazard assumption was graphically assessed using plots of Log [-Log (survival time)]. Cases with missing values for one or more variables in the model were excluded from multivariate analysis. Treatment was not included in the model because the treatment choice was closely associated with the assessment of prognosis at the time of diagnosis.

Finally, the validity of the generated score was then assessed for the validation sample; a recent sample and a prospectively followed sample. The predictive accuracy of 3 models: this new score system, JIS score system, and CLIP score system was quantified by calculating the concordance index (C-index), which provides the area under the receiver operating characteristics (ROC) curve for the prediction of death at 3 years, as described previously.¹⁹ A C-index of 0.5 indicates that outcomes are completely random, whereas a C-index of 1.0 indicates that the model is a perfect predictor.

All analyses were performed with R's software (R Foundation for Statistical Computing, Austria).²⁰ $P < 0.05$ was considered statistically significant in all analyses. The results were reported as a hazard ratio with 95% confidence intervals.

RESULTS

As of August 2004, 344 patients (59%) had died. The overall median survival time was 41 months (95% confidence interval, 36 to 46 mo); 1, 3, 5-year survival rates were 86%, 56%, and 35%, respectively. The baseline characteristics of the patients are given in Table 1. The first-time diagnosed HCC, shown as the number of HCC recurrences = 0 in Table 1, amounted to 295 cases, the first recurrence to 185, the second recurrence to 126, the third recurrence to 90, and more than the fourth recurrence to 165. Most cases were in the Child-Pugh A category. The baseline characteristics of the tumor are given in Table 2.

Nine variables were separately found to be associated with the outcome in univariate analysis of

TABLE 2. Characteristics of the Tumor

	Training Sample	Validation Sample
	No. Patients	No. Patients
Number of tumor		
1/2/3/4/≥5	186/113/57/36/186	112/56/28/18/69
Largest size of tumor (cm)		
≤2.0/2.1-3.0/3.1-5.0/≥5.1	270/163/91/54	128/82/44/29
Vascular invasion		
Yes/no	534/44	266/17
Tumor factor [3 nodule less than 3 cm, vascular invasion (-)]		
Yes/no	285/293	159/124
AFP category (ng/mL)		
≤10/10-10 ² /10 ² -10 ³ />10 ³	137/230/129/82	65/108/70/40
PIVKA-II (mAU/mL) (unknown = 81)		
≤10 ² /10 ² -10 ³ /10 ³ -10 ⁴ />10 ⁴	327/118/64/27	110/58/20/14

11 variables (as shown in Table 3). Forward stepwise selection by Akaike information criterion was used to identify baseline predictors of 9 variables. Five variables were selected: the Child-Pugh score, the number of tumors, AFP, vascular invasion, and the number of HCC recurrences. To better reflect the treatment response, we combined 2 factors to create a single factor: we replaced "the number of tumors and vascular invasion" with "3 nodules less than 3 cm and none of vascular invasion, or not," called the tumor factor. This was done because the criterion "3 nodules less than 3 cm" reflects the possibility of complete response to ablation treatment²¹ and was useful in the current clinical setting. We finally chose 4 factors for a new prognostic classification: the Child-Pugh score, tumor factor, AFP, and the number of HCC recurrences. These 4 covariates showed correlation with survival in the Cox regression analysis.

Each covariate selected by means of forward stepwise methods was divided into 2 categories to derive a simple scoring system. The cut-off levels were chosen where each estimated regression coefficient of the final Cox model was almost the same, that is, we made the relative prognostic weight of covariates the same, around 2 each (shown as in Table 4). A new scoring system was derived to assign scores (0/1) to each covariate of the final model as shown in Table 4. This classification was relatively easy to calculate by summing up each individual score of the 4 covariates. Five risk groups were constituted according to the score distribution. The survival curve of 578 patients calculated by the Kaplan-Meier method is shown in Figure 2A.

We assessed the new score system for 283 patients for the validation sample; prospectively obtained from 2002 to 2003 in Figure 2B. This result validated our scoring system and showed that it can be applied in today's clinical setting. This applicability to the present-day situation is very important, because diagnostic and

TABLE 1. Characteristics of Patients

Variables	Training Sample	Validation Sample
	No. Patients	No. Patients
Median age, y (range)	64 (21-85)	67 (35-83)
Male (%)	425 (73.5)	192(67.8)
Cause of parenchymal disorder		
HBV/HCV/HB+HC	54/486/10	27/227/4
Alcoholic	8	10
Others	20	15
Child-Pugh score (unknown = 1)		
5-6 (A)/7-9 (B)/10-12 (C)	342/218/18	192/79/11
Number of HCC recurrence		
0/1/2/3/≥4	201/123/88/62/104	94/62/38/28/61

HBV indicates Hepatitis B virus; HCV, Hepatitis C virus.

TABLE 3. Univariate Analysis of Clinical Findings for Survival

Variables	No. Patients	O/E Ratio	P	DOF
Sex			0.00168	1
Male/female	425/153	1.11/0.73		
Age			0.00284	3
$\leq 50/50-60/60-70/\geq 70$	37/118/291/132	0.53/0.87/1.19/0.86		
Etiology			0.147	3
HCV/HBV/HB + HC/the others	486/54/10/28	1.03/0.9/1.38/0.54		
Number of HCC recurrence			< 0.0001	4
0/1/2/3/ ≥ 4	201/123/88/62/104	0.57/0.93/1.2/1.33/2.1		
Child-Pugh stage			< 0.0001	2
A/B/C	342/218/18	0.75/1.49/2.72		
Largest size of tumor (cm)			0.00467	3
$\leq 2.0/2.1-3.0/3.1-5.0/\geq 5.1$	270/163/91/54	0.86/1.06/1.16/1.65		
Number of tumor			< 0.0001	4
1/2/3/4/ ≥ 5	186/113/57/36/186	0.52/0.95/0.97/1.04/2.03		
Vascular invasion			< 0.0001	1
Yes/no	534/44	0.93/3.78		
Tumor factor [3 nodules less than 3 cm, vascular invasion (-)]			< 0.0001	1
Yes/no	285/293	0.67/1.53		
AFP (ng/mL)			< 0.0001	3
$\leq 10/10-10^2/10^2-10^3/> 10^3$	137/230/129/82	0.56/0.95/1.2/2.19		
PIVKA-II (mAU/mL)			< 0.0001	3
$\leq 10^2/10^2-10^3/10^3-10^4/> 10^4$	327/118/64/27	0.76/1.34/1.8/3.65		

DOF indicates degree of freedom; O/E ratio, observed/expected ratio; HBV, Hepatitis B virus; HCV, Hepatitis C virus.

therapeutic procedures for HCC have been improved over recent years.

Finally, the prognostic ability of the new scoring system was compared with CLIP score system and the JIS score system. Kaplan-Meier survival curves were shown in Figs. 2C, D). In addition, the predictive accuracy of 3 models was quantified by calculating a C-index, which provides the area under the ROC curve (as shown in Fig. 3). CLIP stage and JIS scoring had a C-index of 7.05 and 6.93, respectively. This new scoring system had a C-index of 7.23. Our scoring system could discriminate the survival most precisely among them.

DISCUSSION

This article revealed that the number of HCC recurrences is a prognostic factor as well as the reserved liver function and the spreading of HCC, and we have

proposed a new scoring system, comprised of 4 parameters: the number of HCC recurrences, the Child-Pugh score, the tumor factor of "3 nodules less than 3 cm and none of vascular invasion," and the AFP level. Each of these parameters has so far been reported to affect patient survival. The occurrence of HCC recurrence reflects disease progression.³⁻⁵ The Child-Pugh score is a well-recognized prognostic variable and reflects reserved liver

TABLE 4. New Scoring System

Variables	Score		RR
	0	1	
Number of HCC recurrence (n = 578)	0 or 1 (n = 324)	≥ 2 (n = 254)	2.26
Child-Pugh score (n = 578)	5-7 (n = 486)	≥ 8 (n = 92)	2.25
Tumor factor (n = 578)	Yes (n = 285)	No (n = 293)	1.90
AFP category (ng/ml) (n = 578)	≤ 1000 (n = 496)	≥ 1001 (n = 82)	2.08

RR indicates risk ratio of Score 1 compared with Score 0, assessed by multivariate analysis.




FIGURE 2. Kaplan-Meier-estimated survival curves. A, By our new scoring system in training samples. B, By our new scoring system in validation samples. C, By the CLIP score system in validation samples. D, By the JIS score system in validation samples.




FIGURE 3. Discriminatory ability for the prediction of death at 3 years, evaluated by receiver operating characteristics curves of the new scoring, CLIP, and JIS staging systems.

function.^{6,7} The criterion of 3 nodules less than 3 cm is related to the treatment response. Ablation therapy is highly effective for tumors smaller than 3 cm, achieving complete responses of around 80% to 100%.²² The achievement of a complete and sustained response is an independent prognostic value.²³ AFP is also a well-recognized prognostic variable, and reflects the degree of cellular differentiation and the spreading of the tumor.²⁴ In the present study, these parameters were independent predictors of survival actually. Elevation of each parameter indicates the progression of HCC. As a result, this new scoring system reflects the spreading of HCC, the response to treatment, and the reserved liver function. In addition, our system is based on not pathologic but easily obtainable and reproducible clinical information. Therefore, this scoring system should be useful in many clinical settings.

A high possibility of recurrence is one of the major characteristics of HCC. Recurrences from either intrahepatic metastasis or de novo HCC exceed 50% at 3 years, even with hepatic resection as curative therapy.³⁻⁵ The more the HCC recurs, the more the prognosis deteriorates because of treatment-induced liver damage and/or tumor progression. In clinical settings, it is very important to carefully follow HCC patients to detect recurrence as early as possible. More and more patients have been able to be frequently treated for recurrent HCC and prolong their survival. What is needed is a treatment strategy based on appropriate cancer staging systems for not only first-time diagnosed HCC but also for recurrent HCC. However, there has been no study reported on the prognosis of recurrent patients. Here, we first showed recurrence to be a prognostic factor with a Cox regression model, and furthermore developed a new scoring system to predict the prognosis of HCC patients including recurrent HCC patients.

What is the problem with applying the other staging systems for the recurrent cases? All of the following staging systems: the CLIP score system,⁶ BCLC staging⁷ and JIS scoring system⁸ were derived from the analysis for first-time diagnosed HCC and were applied only at the initial treatment. Because hypothetical population is different between first-time HCC patients and all HCC patients, their baseline predictors for survival differ from the new scoring system. Indeed, the distributions of both the number of tumor and the largest size of HCC are significantly different between first-time HCC cases and all HCC patients in our cohort (data not shown). As a result, JIS system and CLIP score system may have poor stratification of survival. The goal of cancer staging is to separate patients into different groups on the basis of their predicted survival to help determine the most appropriate treatment modality. Therefore, it is unreasonable to apply their systems for recurrent HCC patients.

Although further evaluation is needed, this scoring system can be useful for conducting interventional trials. With the spread of routine screening and follow-up, the number of recurrent HCC patients can increase. More effective strategies to treat recurrent patients will be needed. In addition, a new modality of treatment will be necessary for HCC management, particularly for score 2 and 3 patients. Interventional trials may be needed to determine the most appropriate therapy for the patients in each group. This scoring system, because of good incorporation between prognosis estimation and potential treatment advances, may be useful for planning and evaluating interventional trials. It would allow us to follow a well-established treatment schedule and select the best treatment modality for each patient when managing long-term-surviving HCC patients.

REFERENCES

- Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. *J Hepatol*. 2003;38(suppl 1):S136-S149.
- Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology*. 2002;122:1609-1619.
- Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. *Cancer*. 1993;71:19-25.
- Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. *Gastroenterology*. 1995;108:768-775.
- Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. *Hepatology*. 2000;32:1224-1229.
- The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. *Hepatology*. 1998;28:751-755.
- Llovet JM, Bruix C, Bruix J. Prognostic staging system for hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*. 1999;19:329-338.
- Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitation, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J Gastroenterol*. 2003;38:207-215.

9. Chevret S, Trnchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome HepatoCellulaire. *J Hepatol*. 1999;31:133-141.
10. The Cancer of the Liver Italian Program (CLIP) investigation. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. *Hepatology*. 2000;31:840-845.
11. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. *Hepatology*. 2004;40:1396-1405.
12. Taouli B, Losada M, Holland A, et al. Magnetic resonance imaging of hepatocellular carcinoma. *Gastroenterology*. 2004;127:S144-S152.
13. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. *Gastroenterology*. 2004;127:S133-S143.
14. Van Houwelingen JC, Le Cessie JC. Predictive value of statistical models. *Stat Med*. 1990;9:1303-1325.
15. Kaplan E, Meter P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedure. *J Roy Stat*. 1972;135:185-206.
17. Akaike H. A new look at the statistical model identification. *IEEE Trans Automatic Control*. 1974;AC-19:716-723.
18. Cox DR. Regression models and life tables. *J R Stat Soc*. 1972; B34:187-220.
19. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. *Clin Cancer Res*. 2004; 10:5464-5474.
20. Development Core Team. R: *A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2004.
21. Vilana R, Bruix J, Bru C, et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. *Hepatology*. 1992;16:353-357.
22. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology*. 2002;35:519-524.
23. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. *Radiology*. 1995;197:101-108.
24. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. *Cancer* 1989;64: 1700-1710.

Original Article

Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

Nao Kurashige,¹ Naoki Hiramatsu,¹ Kazuyoshi Ohkawa,¹ Tsugiko Oze,¹ Yuko Inoue,¹ Mika Kurokawa,¹ Takayuki Yakushijin,¹ Takumi Igura,¹ Shinichi Kiso,¹ Tatsuya Kanto,¹ Tetsuo Takehara,¹ Shinji Tamura,¹ Akinori Kasahara,¹ Masahide Oshita,² Taizo Hijioka,³ Kazuhiro Katayama,⁴ Harumasa Yoshihara,⁵ Eijirou Hayashi,⁶ Yasuharu Imai,⁷ Michio Kato⁸ and Norio Hayashi¹

¹Osaka University, ²Osaka Police Hospital, ³National Organization Osaka Minami Medical Center, ⁴Osaka Kouseinenkin Hospital, ⁵Osaka Rousal Hospital, ⁶Ikeda City Hospital, ⁷National Hospital Organization Osaka National Hospital, Osaka, and ⁸Kinki Central Hospital, Hyogo, Japan

Aim: Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM-resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM-resistant virus in CHB patients treated with LAM.

Methods: The subjects were 190 CHB patients in continuous LAM therapy (139 males, mean age 50 years, 87 HBeAg-positive). The mean duration of follow-up was 39 months (range 12–104). The initial viral response (IVR) was defined as HBV DNA < 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) (<40 IU/L) at 6 months.

Results: IVR was positive in 86% of the patients. The cumulative emergence rates of LAM-resistant virus were 10% at 1 year, 30% at 2 years and 46% at 3 years. In univariate analysis, factors contributing to the emergence of LAM-resistant

virus were baseline HBV DNA > 6.5 logcopies/mL ($P = 0.0044$), HBeAg-positivity ($P = 0.0062$), IBR ($P = 0.01$) and IVR ($P < 0.0001$). The cumulative emergence rates of LAM-resistant virus in IVR-positive and -negative patients were 4% and 41% at 1 year, and 41% and 79% at 3 years. In multivariate analysis, only IVR was an independent factor affecting the emergence of LAM-resistant virus ($P < 0.0001$).

Conclusion: IVR is a useful factor for predicting the emergence of LAM-resistant virus in CHB patients treated with LAM. For IVR-negative patients, therapeutic options other than LAM monotherapy should be used because of the high incidence of the emergence of LAM-resistant virus.

Key words: chronic hepatitis B, initial viral response, lamivudine monotherapy, lamivudine-resistant virus

INTRODUCTION

MORE THAN 350 million people are chronically infected with hepatitis B virus (HBV) worldwide.¹ Chronic HBV infection eventually leads to the development of cirrhosis and hepatocellular carcinoma (HCC), and raises the risk of hepatic disease-related death.

Nucleos(t)ide analogs are widely used to suppress HBV replication and the progression of HBV-related liver diseases. Lamivudine (LAM), the first approved nucleoside analog for chronic HBV infection, has been shown to suppress viral replication and disease activity.² In addition, LAM therapy has recently been reported to reduce the incidence of HCC, the risk of major complications and to improve survival.^{3,4} However, the relatively high incidence of LAM resistance is a serious problem in the case of LAM therapy for chronic HBV infection. The emergence of LAM-resistant HBV is linked to the reappearance of active viral replication, followed by the worsening of liver disease.

LAM-resistant HBV is based on point mutation within the YMDD motif of the reverse transcriptase domain of

Correspondence: Dr Naoki Hiramatsu, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Email: hiramatsu@gh.med.osaka-u.ac.jp
Received 24 August 2007; revision 9 October 2007; accepted 14 October 2007

HBV (YMDD mutation).^{5,6} The emergence rates of the mutant virus have been reported to be 24% at 1 year and 70% at 4 years from the start of treatment.⁷

Recent work has shown that newly developed nucleos(t)ide analogs, such as adefovir dipivoxil (ADV) and entecavir (ETV), are also useful agents for controlling patients with chronic HBV infection.⁸⁻¹¹ In particular, the drug-resistant mutant virus has been reported to appear less frequently in cases of treatment with ADV and ETV than with LAM.^{12,13} For this reason, LAM has been replaced by ADV and ETV for the treatment of chronic hepatitis B. However, there are still a considerable number of patients with chronic HBV infection who are already on continuous LAM therapy. Thus, further clarification is needed of what factors influence the emergence of the LAM-resistant HBV in LAM treatment for chronic HBV infection.

For a more precise evaluation, we investigated baseline and on-treatment factors affecting the emergence of LAM-resistant mutant virus in patients with chronic hepatitis B treated with LAM.

METHODS

Patients and treatment

THIS STUDY WAS conducted at nine institutions in the Osaka area of Japan (Osaka Police Hospital, Osaka Minami Medical Center, Osaka Kouseinenkin Hospital, Osaka Rousai Hospital, Kinki Central Hospital, Ikeda City Hospital, Osaka National Hospital, Otemae Hospital and Osaka University Hospital). The subjects were 190 consecutive patients with chronic hepatitis B who underwent continuous LAM therapy for more than 12 months. All patients tested positive for hepatitis B surface antigen (HBsAg) or had detectable levels of HBV DNA in their sera by the polymerase chain reaction (PCR)-based method (for 100 patients)¹⁴ or the transcription-mediated amplification (TMA) method (for 90 patients).¹⁵ Exclusion criteria were patients with antihepatitis C antibody, antihuman immunodeficiency virus antibody and other forms of liver diseases (alcoholic liver disease, drug-induced liver disease and autoimmune hepatitis). Forty-one (22%) patients had previously received interferon (IFN)- α therapy for 24 weeks.

All patients were treated with 100 mg of LAM daily. After the beginning of the therapy, liver function tests and HBV DNA were measured every other month for the first 6 months and every two months thereafter. HBeAg and anti-HBe were tested every 6 months. In 33

Table 1 Patient characteristics

Gender (male/female)	139/51
Age (years)	50 \pm 11
Chronic hepatitis/liver cirrhosis	113/77
Hepatocellular carcinoma	14 (7%)
AST (IU/L)	122 \pm 157
AST (IU/L)	177 \pm 236
ALT (\leq 1-2/2-5/ $>$ 5 \times UIN)	22/53/65/50
Platelet ($10^3/mm^3$)	12.6 \pm 5.1
Prothrombin time (%)	71.5 \pm 16.6
HBV DNA (logcopies/mL)	6.5 (3.0-7.6<)
HBeAg (positive/negative)	87/103
Combination with interferon	33 (17%)
Duration of treatment (months)	38.9 \pm 17.5

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; UIN, upper limit normal.

patients (18%), combination therapy with IFN was carried out for the initial 6 months. Three or six megauunits of natural IFN- α were administered daily for the first 2 weeks and three times a week thereafter, followed by LAM monotherapy. The mean follow-up period of the 190 patients was 39 (range 12-104) months. The LAM-resistant YMDD mutant virus was detected by the PCR-enzyme-linked minisequence (ELMA) assay¹⁶ when the virological or biochemical breakthrough was observed. The YMDD mutant virus was found in 86 (45%) patients during follow-up. Fifty-eight of these patients underwent ADV therapy in addition to ongoing LAM treatment and were excluded from the follow-up when ADV administration began. In this study, the initial viral response (IVR) was defined as HBV DNA $<$ 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) ($<$ 40 IU/L) after 6 months of therapy.

The patients' clinical characteristics are shown in Table 1. There were 139 males and 51 females, ranging in age from 25 to 75 (mean 50) years. Of them, 113 (59%) patients were diagnosed as having chronic hepatitis and the remaining 77 patients (41%) as having cirrhosis according to liver histology and/or the imaging procedure. HCC was developed in 14 (7%) patients. The aspartate aminotransferase (AST) at baseline was 122 \pm 157 IU/L, and the ALT at baseline was 177 \pm 236 IU/L. Abnormal ALT was observed in 168 (88%) patients. Eighty-seven patients (46%) tested positive for HBeAg. The median HBV DNA at baseline was 6.5 (range 3.0 to 7.6<) logcopies/mL.

HBV testing

HBsAg, hepatitis B e antigen (HBeAg) and antihepatitis B e antibody (anti-HBe) were examined by chemiluminescent immunoassay or enzyme immunoassay.

The HBV DNA level was measured by the PCR-based method (Amplicor HBV monitor; Roche Diagnostics, Tokyo, Japan)¹⁴ or the TMA method (TMA-HPA; Fujirebio, Tokyo, Japan),¹⁵ which have lower detection limits of 2.6 and 3.7 logcopies/mL, respectively. The LAM-resistant YMDD mutant virus was examined by the PCR-ELMA method.¹⁶

Statistical analysis

Comparisons of categorical and continuous variables between groups were done by the χ^2 -test, Student's *t*-test and Mann-Whitney's *U*-test. The cumulative emergence rates of LAM-resistant virus were evaluated with the Kaplan-Meier's curve and the differences between groups were analyzed by the log-rank test. For multivariate analysis to investigate factors affecting the cumulative emergence rate of LAM-resistant virus, Cox proportional hazard regression analysis was carried out. A *P*-value of less than 0.05 (two-tailed) was considered to be statistically significant.

RESULTS

Therapeutic efficacy and the emergence of LAM-resistant mutant virus

AMONG THE 190 patients with chronic hepatitis B who underwent continuous LAM therapy, reduction of HBV DNA to less than 4 logcopies/mL was observed in 86% (163/190) at 6 months, 89% (151/170) at 1 year,

88% (83/94) at 2 years and 89% (48/54) at 3 years of the treatment. Normalization of ALT was achieved by 77% (146/190) at 6 months, 83% (141/170) at 1 year, 81% (76/94) at 2 years and 83% (45/54) at 3 years. Among the 87 HBeAg-positive patients, HBeAg was cleared in 22% (19/86) at 6 months, 26% (21/80) at 1 year, 22% (11/50) at 2 years and 43% (16/37) at 3 years. As for the virological and biochemical response at 6 months of therapy, 163 (86%) of the patients achieved IVR, whereas IBR was seen in 146 (77%) of patients.

When the various patient characteristics were compared between IVR-positive and -negative patients (Table 2), HBV DNA at baseline tended to be lower in patients showing IVR (median 6.5 [range 3.0 to 7.6<] logcopies/mL) than in those who did not show IVR (median 7.3 [range 4.3 to 7.6<] logcopies/mL) ($P < 0.0001$). IVR-negative patients had higher HBeAg positivity at baseline than IVR-positive patients (81% vs 40%, $P = 0.01$). As for the emergence of LAM-resistant mutant virus during follow-up, it was detected more frequently in IVR-negative patients (21/27, 78%) than in IVR-positive patients (65/163, 40%) ($P = 0.002$).

Among the 190 patients examined in this study, the emergence of LAM-resistant YMDD mutant virus occurred in 86 (45%) patients during follow-up. The cumulative probabilities of the emergence of the YMDD mutant virus were 10% at 1 year, 30% at 2 years and 46% at 3 years.

Factors affecting the emergence of LAM-resistant mutant virus

Factors affecting the cumulative probability of the emergence of the YMDD mutant virus were investigated using

Table 2 Comparison of patient characteristics between IVR-positive and -negative patients

	IVR (n = 163)	Non-IVR (n = 27)	P-value
Gender (male/female)	118/45	21/6	NS
Age (years)	50 ± 11	48 ± 12	NS
Chronic hepatitis/liver cirrhosis	91/72	22/5	NS
Hepatocellular carcinoma	13 (8.0%)	1 (4%)	NS
AST (IU/L)	131 ± 167	69 ± 34	NS
ALT (IU/L)	190 ± 252	100 ± 55	NS
ALT ($\leq 1-2/2-5/>5 \times$ ULN)	21/43/52/47	1/10/13/3	NS
HBV DNA (logcopies/mL)	6.5 (3.0-7.6<)	7.3 (4.3-7.6<)	<0.0001
HBeAg (positive/negative)	65/98	22/5	0.01
Combination with interferon	27 (17%)	6 (22%)	NS
Emergence of LAM-resistant viruses	65 (40%)	21 (78%)	0.002
Duration of treatment (months)	39.2 ± 17.2	37.3 ± 19.1	NS

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; IVR, initial viral response; LAM, lamivudine; NS, not significant; ULN, upper limit normal.




Figure 1 Cumulative emergence rate of lamivudine (LAM)-resistant virus in patients with chronic hepatitis B virus (HBV) infection treated with LAM according to: (a) HBV DNA at baseline; (b) hepatitis B e antigen (HBeAg) status; (c) the presence or absence of initial biochemical response (IBR); and (d) the presence or absence of initial viral response (IVR).

both univariate and multivariate analyses. Nine baseline and on-treatment factors – gender, age, liver disease (chronic hepatitis or cirrhosis), ALT at baseline, HBeAg positivity, HBV DNA at baseline, combination therapy with IFN- α , presence of IBR and presence of IVR – were examined. The cumulative emergence of LAM-resistant virus was significantly higher in patients with baseline HBV DNA > 6.5 logcopies/mL than in those with HBV DNA \leq 6.5 logcopies/mL ($P = 0.0044$) (Fig. 1a). HBeAg-positive patients revealed a significantly higher emergence rate of the LAM-resistant virus than HBeAg-negative patients ($P = 0.0062$) (Fig. 1b). A significant difference was also seen in the cumulative emergence of the YMDD mutant virus between IBR-positive and -negative patients ($P = 0.01$) (Fig. 1c). Furthermore, the

cumulative emergence of LAM-resistant mutant virus was much higher in the IVR-negative patients than in the IVR-positive patients ($P < 0.0001$) (Fig. 1d). The cumulative emergence rates of LAM-resistant virus in the IVR-positive and -negative patients were 4% and 41% at 1 year, 25% and 69% at 2 years, and 41% and 79% at 3 years, respectively. Gender, age, liver disease, ALT at baseline and combination therapy of IFN- α did not show a significant relation with the emergence of the YMDD mutant virus. When factors influencing the higher cumulative emergence of LAM-resistant virus were searched for by multivariate analysis, only the absence of IVR was selected as a significant independent factor ($P < 0.001$) (Table 3), with high HBV DNA, HBeAg positivity and the absence of IBR not being selected.

Table 3 Factors associate with emergence of LAM-resistant virus determined by multivariate analysis

	Hazard ratio	95% confidence interval	P-value
Gender			
0: male	1	0.497-1.455	0.55
1: female	1.176		
Age			
0: ≤50	1	0.640-1.700	0.87
1: >50	0.959		
Chronic hepatitis/liver cirrhosis			
0: CH	1	0.656-1.740	0.79
1: LC	0.935		
Pretreatment ALT (IU/L)			
0: ≤200	1	0.605-1.818	0.87
1: >200	0.953		
HBV DNA (logcopies/mL)			
0: ≤6.5	1	0.394-1.125	0.13
1: >6.5	1.502		
HBeAg			
0: negative	1	0.499-1.337	0.42
1: positive	1.225		
Combination therapy with interferon			
0: no	1	0.410-1.303	0.29
1: yes	1.368		
IBR			
0: positive	1	0.483-1.312	0.37
1: negative	1.256		
IVR			
0: positive	1	0.159-0.536	<0.001
1: negative	3.425		

HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; IBR, initial biochemical response; IVR, initial viral response; LAM, lamivudine.

DISCUSSION

IN LAM THERAPY for patients with chronic HBV infection, the emergence of a LAM-resistant YMDD mutant virus is a serious problem, because it inevitably restricts the antiviral efficacy of LAM. To resolve this, detailed studies are needed to identify factors related to the emergence of the YMDD mutant virus. To date, a few investigators have suggested male gender, advanced age, high baseline ALT, the presence of severe acute exacerbation of the liver disease, high baseline HBV DNA and HBeAg-positivity as possible predictors of the emergence of LAM-resistant virus.^{7,17,18} Lower body surface area was also reported as a significant factor for virological and biochemical therapeutic effect.¹⁹ In the present study, we studied 190 patients with chronic hepatitis B treated with LAM and investigated baseline and on-treatment factors affecting the emergence of LAM-resistant mutant virus. Univariate analysis revealed that two baseline factors, high HBV DNA and HBeAg posi-

tivity, had a relation to the high incidence of the YMDD mutant virus, which is consistent with previous reports.^{7,17,18} In addition, two on-treatment factors, IBR and IVR, were found to be correlated with the emergence of LAM resistance. Patients who did not show IVR had a 3.4-fold higher incidence of the emergence of the YMDD mutant virus than those who did show IVR. This agrees with a previous report that the HBV DNA level after 6 months of therapy may be a determinant for subsequent occurrence of a LAM-resistant mutant virus.²⁰ Multivariate analysis showed that only the absence of IVR was a significant factor contributing to the emergence of LAM-resistant virus. Baseline HBV DNA and HBeAg status were not selected as significant factors by multivariate analysis probably because of the tendency for higher HBV DNA and high frequency of HBeAg positivity in IVR-negative patients compared with IVR-positive patients. It is particularly interesting that the absence of IVR, rather than other baseline and on-treatment factors, was a powerful independent pre-